PUSHPARANEE BABUSUKUMAR: Open Payments
NPI 1003919697 · KENOSHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 25 payments from 11 companies in 2025. Trend: 2023 $58 · 2024 $484 · 2025 $499
Food & beverage: $499
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Neurocrine BioSciences, Inc. | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| ABBVIE INC. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| Lundbeck LLC | 2 | $42 |
| Alkermes, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: INGREZZA, FANAPT, VRAYLAR, CAPLYTA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, REXULTI, ABILIFY MAINTENA.
Industry payments across WI — which companies pay providers there.
